.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,463,116

« Back to Dashboard

Claims for Patent: 5,463,116

Title: Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
Abstract:Stable crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine may be produced by treating this compound with a solvent at a temperature of at least 10.degree. C. and forming crystals in the solvent at a temperature of at least 10.degree. C. For example, crystals may be formed by crystallization out of solution, or may be formed from solid particles of the compound suspended in a solvent. Crystals formed in this way have different melting point, infra red spectrum and X-ray diffraction patterns from previously known forms of the compound and have enhanced processability, e.g., stability to grinding.
Inventor(s): Sumikawa; Michito (Kawasaki, JP), Koguchi; Yoshihito (Kawasaki, JP), Ohgane; Takao (Kawasaki, JP), Irie; Yasuo (Kawasaki, JP), Takahashi; Satoji (Yottukaichi, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP)
Application Number:08/190,460
Patent Claims: 1. Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine having at least one of the following properties:

(a) a melting point in the range of 136.degree.-142.degree. C.

(b) a powder X-ray diffraction pattern with reflection maxima at 2.theta. of about 8.1.degree., 13.1.degree., 19.6.degree. and 19.9.degree.;

(c) an infra red absorption spectrum with absorption bands in the region of 1714, 1649, 1542 and 1214 cm.sup.-1.

2. Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine according to claim 1 having all three of the properties (a), (b) and (c).

3. Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine having at least one of an X-ray powder diffraction pattern as shown in FIG. 3 and an infra red spectrum as shown in FIG. 4.

4. Crystals according to any one of claims 1 and 3 in the substantial absence of solvent.

5. A pharmaceutical composition comprising an effective amount of crystals according to claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

6. A method for the production of crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine having at least one the following properties:

(a) a melting point in the range of 136.degree.-142.degree. C.;

(b) a powder X-ray diffraction pattern with reflection maxima at 2.theta. of about 8.1.degree., 13.1.degree., 19.6.degree. and 19.9.degree.;

(c) an infra red absorption spectrum with absorption bands in the region of 1714, 1649, 1542 and 1214 cm.sup.-1, comprising dissolving or suspending an N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine not possessing any of said properties in a solvent in which it is completely or incompletely soluble at a temperature of at least 15.degree. C. and up to the boiling point of the solvent and permitting said crystals to crystallize from or form in said solvent at a temperature of 15.degree. C. of in excess thereof.

7. The method according to claim 6, wherein the N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine is dissolved in a solvent in which it is soluble at a temperature greater than 15.degree. C. to form a solution and from which it may be precipitated by cooling to a lower temperature of 15.degree. C. or higher and crystals are then crystallized from the solution at a temperature of 15.degree. C. or in excess thereof by reducing the temperature of the solution to a temperature of 15.degree. C. or in excess thereof.

8. The method according to claim 6, wherein the N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine is dissolved in a first solvent from which it may be precipitated by addition of a second solvent and the crystallization from solution in the first solvent is effected at a temperature of 15.degree. C. or in excess thereof by adding to the solution a second solvent miscible with the first solvent selected such that the solubility of said N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine in the mixture of the first solvents and second solvent is less than in the first solvent, the solubility being reduced to an extent such that crystals crystallize from the solvent mixture at a temperature in excess of 15.degree. C.

9. The method according to claim 6, wherein the N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine is combined at a temperature of at least 15.degree. C. with a solvent in which it is incompletely soluble at that temperature to form a suspension of solid N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine, and said suspension is maintained at a temperature of at least 15.degree. C., thereby to form said crystals from said solids.

10. The method according to claim 6 further comprising separating said crystals from the solvent at a temperature in excess of 15.degree. C.

11. The method according to claim 7, wherein the solvent is a mixture of a first solvent selected from the group consisting of acetone, ethanol and isopropanol with water as a second solvent.

12. The method according to claim 11, wherein the concentration of the first solvent is from 30 to 60 vol % of the solvent mixture.

13. The method according to claim 11, wherein the temperature of the solution is from 15.degree. to 50.degree. C.

14. The method according to claim 8, wherein the first solvent is selected from the group consisting of acetone, ethanol and isopropanol, and the second solvent is water.

15. The method according to claim 14, wherein the temperature of solution is from 15.degree. to 50.degree. C.

16. The method according to claim 9, wherein the solvent is a mixture of a first solvent selected from the group consisting of acetone, ethanol and isopropanol with water as a second solvent.

17. The method according to claim 16, wherein the concentration of first solvent in the solvent mixture is from 25 to 50 vol % of the solvent mixture.

18. The method according to claim 9, wherein the solvent is water.

19. The method according to claim 16, wherein the temperature of the suspension is from 15.degree. to 50.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc